Trial: 201810088

A Phase 1B Multicenter Pre-Surgical Study to Evaluate Immune Biomarker Modulation in Response to Motolimod (VTX-2337) in Combination with Tislelizumab (BGB-A317) in Subjects with Resectable Squamous Cell Carcinoma of the Head and Neck (SCCHN)



Principal Investigator

Adkins, Douglas

Disease Site

Larynx; Lip, Oral Cavity and Pharynx

Learn more about this study at: